First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)
GCT3018-01
Phase 1 other active
Quick answer
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS) for Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome is a Phase 1 program (other) at Genmab A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Genmab A/S
- Indication
- Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
- Phase
- Phase 1
- Modality
- other
- Status
- active